Gilead Sciences CEO sells 102,619 shares, then 9,810

Gilead’s Chairman & CEO paired option exercises with sales of matching share amounts under a Rule 10b5-1 plan adopted February 25, 2026.

Available on EDGAR 11/06/2026 - 05:16 PM EST Accepted by SEC EDGAR 11/06/2026 - 05:15 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O’Day exercised options for 102,619 shares on November 4, 2026, at a $72.34 exercise price, and sold the same number of shares that day at a reported $175.1627 per share. On November 5, he exercised options for 9,810 shares at $72.34 and sold the same number at a reported $175.17 per share. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 112,429 shares ($11.56M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 112,429 shs ($19.69M)

Approx. gross sale proceeds $19.69M

Approx. exercise cost $8.13M

Approx. pre-tax spread $11.56M

Share of Position Sold 16.9%

Type	Security	Shares	Price	Value
Exercise	Non-qualified Stock Option (Right to Buy) ^{F1, F3}	9,810	$0.00	$0.00
Exercise	Common Stock ^F1	9,810	$72.34	$710K
Sale	Common Stock ^F1	9,810	$175.17	$1.72M
Exercise	Non-qualified Stock Option (Right to Buy) ^{F1, F3}	102,619	$0.00	$0.00
Exercise	Common Stock ^F1	102,619	$72.34	$7.42M
Sale	Common Stock ^{F1, F2}	102,619	$175.1627	$17.98M

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 128,310 contracts (Direct); Common Stock — 551,683 shares (Direct)

Holdings Before and After: Non-qualified Stock Option (Right to Buy), 240,739 to 128,310 contracts (Direct); Common Stock, 551,683 to 551,683 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
F2. Sale prices for the transactions reported range from $175.05 to $175.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3. The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Key Figures

Options exercised: 102,619 shares Shares sold: 102,619 shares Sale price: $175.1627 per share +4 more

7 metrics

Options exercised 102,619 shares November 4, 2026

Shares sold 102,619 shares November 4, 2026

Sale price $175.1627 per share November 4, 2026

Options exercised 9,810 shares November 5, 2026

Shares sold 9,810 shares November 5, 2026

Sale price $175.17 per share November 5, 2026

Exercise price $72.34 per share For both option exercises

Key Terms

Non-qualified Stock Option (Right to Buy), Rule 10b5-1 trading plan, four-year vesting schedule

3 terms

Non-qualified Stock Option (Right to Buy) financial

"Non-qualified Stock Option (Right to Buy)"

Rule 10b5-1 trading plan regulatory

"made pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

four-year vesting schedule financial

"The stock options have a four-year vesting schedule."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GILD shares did its CEO sell?

Daniel Patrick O’Day sold 102,619 shares on November 4, 2026, at a reported $175.1627 per share, and 9,810 shares on November 5 at a reported $175.17 per share. Each sale followed an option exercise for the same number of shares at a $72.34 exercise price. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted February 25, 2026.

What was the vesting schedule for O’Day’s GILD options?

The stock options have a four-year vesting schedule: 25% vest on the first anniversary of the grant date, and the balance vests 6.25% quarterly thereafter until fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/04/2026		M⁽¹⁾		102,619	A	$72.34	654,302	D
Common Stock	11/04/2026		S⁽¹⁾		102,619	D	$175.1627⁽²⁾	551,683	D
Common Stock	11/05/2026		M⁽¹⁾		9,810	A	$72.34	561,493	D
Common Stock	11/05/2026		S⁽¹⁾		9,810	D	$175.17	551,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Option (Right to Buy)	$72.34	11/04/2026		M⁽¹⁾			102,619	⁽³⁾	03/10/2030	Common Stock	102,619	$0	138,120	D
Non-qualified Stock Option (Right to Buy)	$72.34	11/05/2026		M⁽¹⁾			9,810	⁽³⁾	03/10/2030	Common Stock	9,810	$0	128,310	D

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

2. Sale prices for the transactions reported range from $175.05 to $175.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Amy Kim by Power of Attorney for Daniel O'Day	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR